Gretchen Hall
Acute Care · Atlanta, GANPI 1942719000
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 170 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 9.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,439 and has fallen 98.7% since, to $19 in 2025. Among acute care clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 170 payments — averaging $22.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$345
- Bayer$284
- Merck$263
- Lilly USA, LLC$263
- E.r. Squibb & Sons, L.L.C.$260
- Johnson & Johnson$253
- plus $2K from 34 others
What the payments were for
- Food & beverage$3,68498%
- Education$832%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 13 | $345 |
| Bayer | 9 | $284 |
| Merck | 13 | $263 |
| Lilly USA, LLC | 10 | $263 |
| E.r. Squibb & Sons, L.L.C. | 15 | $260 |
| Johnson & Johnson | 8 | $253 |
| Novartis | 12 | $242 |
| Pfizer | 13 | $230 |
| Bristol Myers Squibb | 9 | $176 |
| Seagen Inc. | 5 | $116 |
| Penumbra, Inc. | 1 | $114 |
| Eisai Inc. | 5 | $98 |
| Incyte Corporation | 4 | $94 |
| Sanofi | 4 | $86 |
| Array Biopharma Inc | 4 | $75 |
| AstraZeneca | 4 | $75 |
| Regeneron Healthcare Solutions, Inc. | 3 | $74 |
| AbbVie | 2 | $66 |
| AVEO Pharmaceuticals, Inc. | 4 | $64 |
| Daiichi Sankyo Inc. | 2 | $58 |
| Pharmacosmos Therapeutics Inc. | 3 | $55 |
| Ipsen Biopharmaceuticals, Inc | 3 | $52 |
| Beigene USA, Inc. | 2 | $44 |
| Puma Biotechnology, Inc. | 3 | $38 |
| CSL Behring | 2 | $36 |
| Jazz Pharmaceuticals Inc. | 2 | $35 |
| Karyopharm Therapeutics Inc. | 2 | $29 |
| Stemline Therapeutics Inc. | 1 | $24 |
| Rigel Pharmaceuticals, Inc. | 1 | $24 |
| EMD Serono, Inc. | 1 | $22 |
| Heron Therapeutics, Inc. | 1 | $21 |
| AMAG Pharmaceuticals, Inc. | 1 | $21 |
| GE HealthCare | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $17 |
| Exelixis Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $14 |
| Myovant Sciences Inc. | 1 | $14 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nubeqa$125
- DARZALEX$118
- Indigo System$114
- Trodelvy$105
How this compares
$3,767 in reported general payments places this provider in the 90th percentile of 679 acute care providers in Georgia.
Other acute care in Atlanta
- Sarah WymanAtlanta$10K
- Ayeshia PowellAtlanta$10K
- Michael WattsAtlanta$6K
- Merry NevilleAtlanta$5K
- Annalee EdwardsAtlanta$5K
- Jamie ThreattAtlanta$5K
- Kenya RaglandAtlanta$4K
- Emma HallAtlanta$4K
- Summer DaviesAtlanta$4K
- Darryl TurnerRinggold$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.